Compare AbCellera Biologics Inc (ABCL) vs ConocoPhillips (COP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs ConocoPhillips — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while ConocoPhillips trades at $110.11 (market cap $132.11B). The key difference: ConocoPhillips is far larger — about 56.2× AbCellera Biologics Inc's market cap, and ConocoPhillips pays a 3.1% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | COP | |
|---|---|---|
Market Cap | $2.35B | $132.11B |
Sector | Health | Energy |
52-Week High | $8.12 | $133.80 |
52-Week Low | $2.78 | $85.66 |
Enterprise Value | $1.99B | $149.08B |
Dividend Yield | — | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ConocoPhillips (COP) trades at $108.44, up 3.54% today, with strong analyst support (74.5% buy ratings) and a $148.86 consensus price target suggesting significant upside. The company maintains solid fundamentals with a 12.58% net margin and 11.25% ROE, though revenue has declined from $78.5B in 2022 to $58.9B in 2025. Technical indicators show bearish momentum despite oversold RSI readings, with key support at $102-103 levels.
COP presents a compelling value opportunity with attractive valuation multiples (P/E 17.56, EV/EBITDA 5.81) and consistent cash flow generation. However, investors face risks from volatile oil prices, declining revenue trends, and geopolitical uncertainties affecting energy markets. The upcoming Q2 earnings report on August 6 will be critical for confirming the bullish analyst outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →
